PD-1 抑制剂治疗晚期黑色素瘤的疗效和安全性：系统评价和荟萃分析。
Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.
机构信息
College of Pharmacy, Southwest Minzu University, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan 610041, PR China.
出版信息
Immunotherapy. 2018 Nov;10(15):1293-1302. doi: 10.2217/imt-2018-0116.
AIM
We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma.
STUDY DESIGN
The relevant studies of the randomized controlled trials in melanoma patients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018.
RESULTS
PD-1 inhibitors significantly improved the progression-free survival, overall survival and overall response rate in patients with advanced melanoma. Progression-free survival, overall survival and overall response rate did not vary significantly according to PD-L1 status, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations and type of drug, but varied significantly by control therapy. PD-1 inhibitors were associated with a decreased risk of adverse events compared with ipilimumab, but an increased risk of immune-related events compared with chemotherapy.
CONCLUSION
The PD-1 inhibitors-containing therapy was efficacious in treating advanced melanoma.
目的
我们进行了一项荟萃分析，以系统地评价程序性死亡受体 1（PD-1）抑制剂治疗晚期黑色素瘤的疗效和安全性。
研究设计
检索了黑色素瘤患者接受 PD-1 抑制剂治疗的随机对照试验的相关研究，并进行了系统评价。检索数据库截止至 2018 年 6 月。
结果
PD-1 抑制剂可显著提高晚期黑色素瘤患者的无进展生存期、总生存期和总缓解率。无进展生存期、总生存期和总缓解率与 PD-L1 状态、V-raf 鼠肉瘤病毒癌基因同源物 B1（BRAF）突变和药物类型无关，但与对照治疗显著相关。与伊匹单抗相比，PD-1 抑制剂相关不良事件的风险降低，但与化疗相比，免疫相关不良事件的风险增加。
结论
含 PD-1 抑制剂的治疗方案对晚期黑色素瘤有效。
Zotero 插件